Cargando…
0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial
We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy. Complete healing occurred after 4 weeks in 6 of the 10 RGN-2...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820614/ https://www.ncbi.nlm.nih.gov/pubmed/36613994 http://dx.doi.org/10.3390/ijms24010554 |
_version_ | 1784865505865105408 |
---|---|
author | Sosne, Gabriel Kleinman, Hynda K. Springs, Clark Gross, Robert Hollis Sung, Jihye Kang, Shinwook |
author_facet | Sosne, Gabriel Kleinman, Hynda K. Springs, Clark Gross, Robert Hollis Sung, Jihye Kang, Shinwook |
author_sort | Sosne, Gabriel |
collection | PubMed |
description | We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy. Complete healing occurred after 4 weeks in 6 of the 10 RGN-259-treated subjects and in 1 of the 8 placebo-treated subjects (p = 0.0656), indicating a strong efficacy trend. Additional efficacy was seen in the significant healing (p = 0.0359) with no recurrent defects observed at day 43, two weeks after cessation of treatment, while the one healed placebo-treated subject at day 28 suffered a recurrence at day 43. The Mackie classification disease stage improved in the RGN-259-treated group at Days 29, 36, and 43 (p = 0.0818, 0.0625, and 0.0467, respectively). Time to complete healing also showed a trend towards efficacy (p = 0.0829, Kaplan–Meier) with 0.1% RGN-259. RGN-259-treated subjects had significant improvements at multiple time points in ocular discomfort, foreign body sensation, and dryness which were not seen in the placebo group. No significant adverse effects were observed. In summary, the use of 0.1% RGN-259 promotes rapid healing of epithelial defects in neurotrophic keratopathy, improves ocular comfort, and is safe for treating this challenging population of patients. |
format | Online Article Text |
id | pubmed-9820614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98206142023-01-07 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial Sosne, Gabriel Kleinman, Hynda K. Springs, Clark Gross, Robert Hollis Sung, Jihye Kang, Shinwook Int J Mol Sci Article We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy. Complete healing occurred after 4 weeks in 6 of the 10 RGN-259-treated subjects and in 1 of the 8 placebo-treated subjects (p = 0.0656), indicating a strong efficacy trend. Additional efficacy was seen in the significant healing (p = 0.0359) with no recurrent defects observed at day 43, two weeks after cessation of treatment, while the one healed placebo-treated subject at day 28 suffered a recurrence at day 43. The Mackie classification disease stage improved in the RGN-259-treated group at Days 29, 36, and 43 (p = 0.0818, 0.0625, and 0.0467, respectively). Time to complete healing also showed a trend towards efficacy (p = 0.0829, Kaplan–Meier) with 0.1% RGN-259. RGN-259-treated subjects had significant improvements at multiple time points in ocular discomfort, foreign body sensation, and dryness which were not seen in the placebo group. No significant adverse effects were observed. In summary, the use of 0.1% RGN-259 promotes rapid healing of epithelial defects in neurotrophic keratopathy, improves ocular comfort, and is safe for treating this challenging population of patients. MDPI 2022-12-29 /pmc/articles/PMC9820614/ /pubmed/36613994 http://dx.doi.org/10.3390/ijms24010554 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sosne, Gabriel Kleinman, Hynda K. Springs, Clark Gross, Robert Hollis Sung, Jihye Kang, Shinwook 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial |
title | 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial |
title_full | 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial |
title_fullStr | 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial |
title_full_unstemmed | 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial |
title_short | 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial |
title_sort | 0.1% rgn-259 (thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase iii clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820614/ https://www.ncbi.nlm.nih.gov/pubmed/36613994 http://dx.doi.org/10.3390/ijms24010554 |
work_keys_str_mv | AT sosnegabriel 01rgn259thymosinß4ophthalmicsolutionpromoteshealingandimprovescomfortinneurotrophickeratopathypatientsinarandomizedplacebocontrolleddoublemaskedphaseiiiclinicaltrial AT kleinmanhyndak 01rgn259thymosinß4ophthalmicsolutionpromoteshealingandimprovescomfortinneurotrophickeratopathypatientsinarandomizedplacebocontrolleddoublemaskedphaseiiiclinicaltrial AT springsclark 01rgn259thymosinß4ophthalmicsolutionpromoteshealingandimprovescomfortinneurotrophickeratopathypatientsinarandomizedplacebocontrolleddoublemaskedphaseiiiclinicaltrial AT grossroberthollis 01rgn259thymosinß4ophthalmicsolutionpromoteshealingandimprovescomfortinneurotrophickeratopathypatientsinarandomizedplacebocontrolleddoublemaskedphaseiiiclinicaltrial AT sungjihye 01rgn259thymosinß4ophthalmicsolutionpromoteshealingandimprovescomfortinneurotrophickeratopathypatientsinarandomizedplacebocontrolleddoublemaskedphaseiiiclinicaltrial AT kangshinwook 01rgn259thymosinß4ophthalmicsolutionpromoteshealingandimprovescomfortinneurotrophickeratopathypatientsinarandomizedplacebocontrolleddoublemaskedphaseiiiclinicaltrial |